Disrupting resistance to EGFR-specific tyrosine kinase inhibitors in TP53-mutated lung carcinoma cell lines by proteasome inhibition

被引：0
|
作者：
Orth, Franziska
Schaefer, Benjamin
Harsch, Annika
Weller, Sandra
Beigl, Tobias
Barber, Lynn
Kopp, Hans-Georg
Essmann, Frank
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2532
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2532
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma
    Yeh, Chi-Tai
    Chen, Tzu-Tao
    Satriyo, Pamungkas Bagus
    Wang, Chun-Hua
    Wu, Alexander T. H.
    Chao, Tsu-Yi
    Lee, Kang-Yun
    Hsiao, Michael
    Wang, Liang-Shun
    Kuo, Kuang-Tai
    ONCOGENESIS, 2021, 10 (07)
  • [22] Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
    Thompson, Jonathan R.
    Menon, Smitha P.
    Dy, Grace K.
    ADMET AND DMPK, 2016, 4 (03): : 186 - 211
  • [23] Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases
    Flippot, R.
    Auclin, E.
    Biondani, P.
    Le Rhun, E.
    Adam, J.
    Planchard, D.
    Caramella, C.
    Le Pechoux, C.
    Lacroix, L.
    Gazzah, A.
    Mezquita, L.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S467 - S467
  • [24] Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
    Bruno, Rossella
    Del Re, Marzia
    Cucchiara, Federico
    Petrini, Iacopo
    Ali, Greta
    Crucitta, Stefania
    Proietti, Agnese
    Valleggi, Simona
    Chella, Antonio
    Danesi, Romano
    Fontanini, Gabriella
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [25] Drug Resistance to EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Soh, Junichi
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    ACTA MEDICA OKAYAMA, 2014, 68 (04) : 191 - 200
  • [26] Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)
    Elena María Martínez-Navarro
    Joseba Rebollo
    Ramón González-Manzano
    Manuel Sureda
    Elena Evgenyeva
    Belén Valenzuela
    Francisco José Fernández
    Jerónimo Forteza
    Antonio Brugarolas
    Clinical and Translational Oncology, 2011, 13 : 812 - 818
  • [27] Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)
    Maria Martinez-Navarro, Elena
    Rebollo, Joseba
    Gonzalez-Manzano, Ramon
    Sureda, Manuel
    Evgenyeva, Elena
    Valenzuela, Belen
    Jose Fernandez, Francisco
    Forteza, Jeronimo
    Brugarolas, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (11): : 812 - 818
  • [28] Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
    Uenami, T.
    Mori, M.
    Shiroyama, T.
    Nagatomo, I.
    Ihara, S.
    Komuta, K.
    Suzuki, H.
    Hirashima, T.
    Kimura, M.
    Imamura, F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors
    Lasvergnas, Julie
    Fallet, Vincent
    Duchemann, Boris
    Jouveshomme, Stephane
    Cadranel, Jacques
    Chouaid, Christos
    RESPIRATORY MEDICINE AND RESEARCH, 2023, 84
  • [30] The prevalence of TP53 mutation and primary resistance mechanisms in short-term responders to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Fan, Yun
    Tong, Xiaoling
    Yan, Junrong
    Wu, Xue
    Shao, Yang
    Xu, Yanjun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345